Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
[1]Benjamin J. Solomon, et al. Updated Efficacy and Safety From the Phase 3 CROWN Study of First-Line Lorlatinib vs Crizotinib in Advanced Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC). AACR 2022, Abstract #CT223...
[5] Solomon BJ, Bauer TM, Ignatius Ou SH, et al. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. J ...
[4]Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024 Jan 11;390(2):118-131. [5]Li W, Xiong A, Yang N, et al. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lun...
I want to share something wonderful with you. As a member of the ALKPositive group, I offered to start an Instagram page where photos and stories of ALK+ patients could be shared. I knew it would be special but I had no ideahowspecial. Nor did I realize how movedIwould feel as I ...
Evaluating the Optimal TKI for Patients With ALK Positive Advanced Non-Small-Cell Lung Cancer (aNSCLC) in the First Line (1L) Setting: An Updated Systematic Literature Review (SLR) and Network MetaAnalysis (NMA) . 2024 ISPOR Europe. [3] Solomon BJ, Liu G, Felip E, et al. Lorlatinib ...
The group of ALK fusion positive patients matched with a group of ALK- and EGFR-mutation negative patients as well as a group of EGFR mutation positive patients Results and discussion First, we evaluated PD-L1 expression on the tumor cell membrane in ALK+ NSCLC. A total of 100 lung ...
FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer. News release.注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。如有需要可以咨询一下香港登越药业,专业提供各类进出口服务。 送TA礼物 1楼2025-02-20 11:33回复 ...
Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors M. A. Berry A. R. Bland J. C. Ashton Scientific Reports(2023) Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer ...
2. Mok T, Camidge DR, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann oncology: Off J...